Neuroprotective action of resveratrol

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 6, 2015, Pages 1195-1201

  Bastianetto, Stéphane ^a   Ménard, Caroline ^a,b,c,d   Quirion, Rémi ^a,b  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Ischemia; Kinase; Polyphenol; SIRT 1

Indexed keywords

ANTIOXIDANTS; NEUROPROTECTIVE AGENTS; RESVERATROL; STILBENES;

ANIMALS; APOPTOSIS; DRUG EFFECTS; HUMANS; NEURONS; SYNAPSES;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; STILBENES; SYNAPSES;

EID: 84939952998     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.09.011     Document Type: Review

References (100)

1. Luchsinger J.A., Noble J.M., Scarmeas N. Diet and Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2007, 7:366-372.
2. Morris M.C. The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur. J. Neurol. 2009, 16(Suppl. 1):1-7.
3. Orgogozo J.M., Dartigues J.F., Lafont S., Letenneur L., Commenges D., Salamon R., Renaud S., Breteler M.B. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev. Neurol. 1997, 153:185-192.
4. Obisesan T.O., Hirsch R., Kosoko O., Carlson L., Parrott M. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1. J. Am. Geriatr. Soc. 1998, 46:1-7.
5. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
6. Wu J.M., Hsieh T.C. Resveratrol: a cardioprotective substance. Ann. N. Y. Acad. Sci. 2011, 1215:16-21.
7. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
8. Dumont M., Beal M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 2011, 51:1014-1026.
9. Belguendouz L., Fremont L., Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol. 1997, 53:1347-1355.
10. de la Lastra C.A., Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 2005, 49:405-430.
11. Bastianetto S., Zheng W.H., Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br. J. Pharmacol. 2000, 131:711-720.
12. Vella F., Ferry G., Delagrange P., Boutin J.A. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 2005, 71:1-12.
13. Benoit C.E., Bastianetto S., Brouillette J., Tse Y., Boutin J.A., Delagrange P., Wong T., Sarret P., Quirion R. Loss of quinone reductase 2 function selectively facilitates learning behaviors. J. Neurosci. 2010, 30:12690-12700.
14. Ferry G., Hecht S., Berger S., Moulharat N., Coge F., Guillaumet G., Leclerc V., Yous S., Delagrange P., Boutin J.A. Old and new inhibitors of quinone reductase 2. Chem. Biol. Interact. 2010, 186:103-109.
15. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.C., Wu J.M., Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43:11417-11426.
16. Sakata Y., Zhuang H., Kwansa H., Koehler R.C., Dore S. Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp. Neurol. 2010, 224:325-329.
17. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7217-7222.
18. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
19. Shin S.M., Cho I.J., Kim S.G. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol. Pharmacol. 2009, 76:884-895.
20. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201.
21. Jin F., Wu Q., Lu Y.F., Gong Q.H., Shi J.S. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 2008, 600:78-82.
22. Das S., Das D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets 2007, 6:168-173.
23. Bi X.L., Yang J.Y., Dong Y.X., Wang J.M., Cui Y.H., Ikeshima T., Zhao Y.Q., Wu C.F. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int. Immunopharmacol. 2005, 5:185-193.
24. Candelario-Jalil E., de Oliveira A.C., Graf S., Bhatia H.S., Hull M., Munoz E., Fiebich B.L. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J. Neuroinflammation 2007, 4:25.
25. Kim Y.A., Kim G.Y., Park K.Y., Choi Y.H. Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J. Med. Food 2007, 10:218-224.
26. Meng X.L., Yang J.Y., Chen G.L., Wang L.H., Zhang L.J., Wang S., Li J., Wu C.F. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. Chem. Biol. Interact. 2008, 174:51-59.
27. Zhang F., Liu J., Shi J.S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur. J. Pharmacol. 2010, 636:1-7.
28. Markiewicz I., Lukomska B. The role of astrocytes in the physiology and pathology of the central nervous system. Acta Neurobiol. Exp. (Wars) 2006, 66:343-358.
29. Belanger M., Allaman I., Magistretti P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011, 14:724-738.
30. Quincozes-Santos A., Bobermin L.D., Latini A., Wajner M., Souza D.O., Goncalves C.A., Gottfried C. Resveratrol protects C6 astrocyte cell line against hydrogen peroxide-induced oxidative stress through heme oxygenase 1. PLoS One 2013, 8:e64372.
31. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007, 8:766-775.
32. Wakabayashi N., Slocum S.L., Skoko J.J., Shin S., Kensler T.W. When NRF2 talks, who's listening?. Antioxid. Redox Signal. 2010, 13:1649-1663.
33. Bellaver B., Souza D.G., Souza D.O., Quincozes-Santos A. Resveratrol increases antioxidant defenses and decreases proinflammatory cytokines in hippocampal astrocyte cultures from newborn, adult and aged Wistar rats. Toxicol. In Vitro 2014, 28:479-484.
34. Lee M., Cho T., Jantaratnotai N., Wang Y.T., McGeer E., McGeer P.L. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 2010, 24:2533-2545.
35. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
36. Aisen P.S. The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs 2005, 19:989-996.
37. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 2009, 110:1129-1134.
38. Han Y.S., Zheng W.H., Bastianetto S., Chabot J.G., Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol. 2004, 141:997-1005.
39. Han Y.S., Bastianetto S., Dumont Y., Quirion R. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J. Pharmacol. Exp. Ther. 2006, 318:238-245.
40. Jang J.H., Surh Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 2003, 34:1100-1110.
41. Kwon K.J., Kim H.J., Shin C.Y., Han S.H. Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein kinase pathways. J. Clin. Neurol. 2010, 6:127-137.
42. Richard T., Poupard P., Nassra M., Papastamoulis Y., Iglesias M.L., Krisa S., Waffo-Teguo P., Merillon J.M., Monti J.P. Protective effect of epsilon-viniferin on beta-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry. Bioorg. Med. Chem. 2011, 19:3152-3155.
43. Granzotto A., Zatta P. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Abeta and Abeta-metal complexes toxicity. PLoS One 2011, 6:e21565.
44. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280:37377-37382.
45. Riviere C., Richard T., Vitrac X., Merillon J.M., Valls J., Monti J.P. New polyphenols active on beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 2008, 18:828-831.
46. Jeon S.Y., Kwon S.H., Seong Y.H., Bae K., Hur J.M., Lee Y.Y., Suh D.Y., Song K.S. Beta-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine 2007, 14:403-408.
47. de Vrij F.M., Fischer D.F., van Leeuwen F.W., Hol E.M. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog. Neurobiol. 2004, 74:249-270.
48. Klein W.L. ADDLs & protofibrils - the missing links?. Neurobiol. Aging 2002, 23:231-235.
49. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10417-10422.
50. Klein W.L. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement. 2006, 2:43-55.
51. Feng Y., Wang X.P., Yang S.G., Wang Y.J., Zhang X., Du X.T., Sun X.X., Zhao M., Huang L., Liu R.T. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 2009, 30:986-995.
52. Ladiwala A.R., Lin J.C., Bale S.S., Marcelino-Cruz A.M., Bhattacharya M., Dordick J.S., Tessier P.M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J. Biol. Chem. 2010, 285:24228-24237.
53. Yang H.Q., Pan J., Ba M.W., Sun Z.K., Ma G.Z., Lu G.Q., Xiao Q., Chen S.D. New protein kinase C activator regulates amyloid precursor protein processing in vitro by increasing alpha-secretase activity. Eur. J. Neurosci. 2007, 26:381-391.
54. DeVries-Seimon T.A., Ohm A.M., Humphries M.J., Reyland M.E. Induction of apoptosis is driven by nuclear retention of protein kinase C delta. J. Biol. Chem. 2007, 282:22307-22314.
55. Garrido J.L., Godoy J.A., Alvarez A., Bronfman M., Inestrosa N.C. Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 2002, 16:1982-1984.
56. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., Marambaud P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285:9100-9113.
57. Culmsee C., Monnig J., Kemp B.E., Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 2001, 17:45-58.
58. Albani D., Polito L., Forloni G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J. Alzheimers Dis. 2010, 19:11-26.
59. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
60. Albani D., Polito L., Batelli S., De Mauro S., Fracasso C., Martelli G., Colombo L., Manzoni C., Salmona M., Caccia S., Negro A., Forloni G. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 2009, 110:1445-1456.
61. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54:111-118.
62. Raval A.P., Dave K.R., Perez-Pinzon M.A. Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab. 2006, 26:1141-1147.
63. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., Gan L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 2005, 280:40364-40374.
64. Zhang J., Feng X., Wu J., Xu H., Li G., Zhu D., Yue Q., Liu H., Zhang Y., Sun D., Wang H., Sun J. Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by beta-amyloid through activation of SIRT1/Akt1 pathway. BioFactors 2014, 40:258-267.
65. Tang B.L. Resveratrol is neuroprotective because it is not a direct activator of Sirt1 - a hypothesis. Brain Res. Bull. 2010, 81:359-361.
66. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
67. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., Kim M.K., Beaven M.A., Burgin A.B., Manganiello V., Chung J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
68. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
69. Zamin L.L., Dillenburg-Pilla P., Argenta-Comiran R., Horn A.P., Simao F., Nassif M., Gerhardt D., Frozza R.L., Salbego C. Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of PI3-K pathway. Neurobiol. Dis. 2006, 24:170-182.
70. Das S., Tosaki A., Bagchi D., Maulik N., Das D.K. Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2005, 314:762-769.
71. Bastianetto S., Brouillette J., Quirion R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem. Res. 2007, 32:1720-1725.
72. Menard C., Quirion R. Successful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways. PLoS One 2012, 7:e28666.
73. Dehvari N., Cedazo-Minguez A., Isacsson O., Nilsson T., Winblad B., Karlstrom H., Benedikz E., Cowburn R.F. Presenilin dependence of phospholipase C and protein kinase C signaling. J. Neurochem. 2007, 102:848-857.
74. Cherniack E.P. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br. J. Nutr. 2012, 108:794-800.
75. Menard C., Bastianetto S., Quirion R. Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Front. Cell. Neurosci. 2013, 7:281.
76. Newton A.C. Protein kinase C: poised to signal. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E395-E402.
77. Loegering D.J., Lennartz M.R. Protein kinase C and toll-like receptor signaling. Enzyme Res. 2011, 2011:537821.
78. Wu-Zhang A.X., Newton A.C. Protein kinase C pharmacology: refining the toolbox. Biochem. J. 2013, 452:195-209.
79. LeBlanc A.C. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr. Alzheimer Res. 2005, 2:389-402.
80. Yu W., Mechawar N., Krantic S., Quirion R. Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease. Am. J. Pathol. 2010, 176:2209-2218.
81. Bastianetto S., Krantic S., Chabot J.G., Quirion R. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols. Curr. Alzheimer Res. 2011, 8:445-451.
82. 2+ concentrations are involved in resveratrol protection against apoptosis in rat primary neuron cultures. Acta Pharmacol. Sin. 2007, 28:1724-1730.
83. Gao D., Huang T., Jiang X., Hu S., Zhang L., Fei Z. Resveratrol protects primary cortical neuron cultures from transient oxygen-glucose deprivation by inhibiting MMP-9. Mol. Med. Rep. 2014, 9:2197-2204.
84. Huang T., Gao D., Jiang X., Hu S., Zhang L., Fei Z. Resveratrol inhibits oxygen-glucose deprivation-induced MMP-3 expression and cell apoptosis in primary cortical cells via the NF-kappaB pathway. Mol. Med. Rep. 2014, 10:1065-1071.
85. Campos-Esparza M.R., Sanchez-Gomez M.V., Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 2009, 45:358-368.
86. Bournival J., Quessy P., Martinoli M.G. Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol. 2009, 29:1169-1180.
87. Bureau G., Longpre F., Martinoli M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 2008, 86:403-410.
88. Sato M., Suzuki Y., Okuda T., Yokotsuka K. Contents of resveratrol, piceid, and their isomers in commercially available wines made from grapes cultivated in Japan. Biosci. Biotechnol. Biochem. 1997, 61:1800-1805.
89. Hashim S.N., Schwarz L.J., Boysen R.I., Yang Y., Danylec B., Hearn M.T. Rapid solid-phase extraction and analysis of resveratrol and other polyphenols in red wine. J. Chromatogr. A 2013, 1313:284-290.
90. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36:79-87.
91. Walle T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215:9-15.
92. Virgili M., Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci. Lett. 2000, 281:123-126.
93. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002, 958:439-447.
94. Sinha K., Chaudhary G., Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002, 71:655-665.
95. Frozza R.L., Bernardi A., Hoppe J.B., Meneghetti A.B., Matte A., Battastini A.M., Pohlmann A.R., Guterres S.S., Salbego C. Neuroprotective effects of resveratrol against Abeta administration in rats are improved by lipid-core nanocapsules. Mol. Neurobiol. 2013, 47:1066-1080.
96. Luchsinger J.A., Tang M.X., Siddiqui M., Shea S., Mayeux R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc. 2004, 52:540-546.
97. Kennedy D.O., Wightman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91:1590-1597.
98. Wightman E.L., Reay J.L., Haskell C.F., Williamson G., Dew T.P., Kennedy D.O. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br. J. Nutr. 2014, 112:203-213.
99. Wong R.H., Coates A.M., Buckley J.D., Howe P.R. Evidence for circulatory benefits of resveratrol in humans. Ann. N. Y. Acad. Sci. 2013, 1290:52-58.
100. Chang J., Rimando A., Pallas M., Camins A., Porquet D., Reeves J., Shukitt-Hale B., Smith M.A., Joseph J.A., Casadesus G. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging 2012, 33:2062-2071.